Received May 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Lightheadedness/ Felt fainting; Sweaty; Clammy; hip pain in joint; This non-serious case was reported by a consumer via call center representative and described the occurrence of light headedness in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included parkinson's disease (Parkinson's disease). In MAR-2026, the patient received the 1st dose of Shingrix. In MAR-2026, immediately after receiving Shingrix, the patient experienced light headedness (Verbatim: Lightheadedness/ Felt fainting), sweating (Verbatim: Sweaty), clamminess (Verbatim: Clammy) and pain in hip (Verbatim: hip pain in joint). The outcome of the light headedness, sweating, clamminess and pain in hip were unknown. It was unknown if the reporter considered the light headedness, sweating, clamminess and pain in hip to be related to Shingrix. It was unknown if the company considered the light headedness, sweating, clamminess and pain in hip to be related to Shingrix. Additional Information: GSK Receipt Date: 19-MAY-2026 The patient stated that she received the first dose of the Shingrix vaccine in MAR-2026. She states that almost immediately she felt sweaty, clammy, lightheaded and felt like she would faint. She stated the 12 to 24 hours later she had hip pain in her joint. She stated the hip pain lasted a long time. The batch number was not provided upon follow- up with the reporter.
Parkinson's disease (Parkinson's disease)